Synthesis and antifibrillatory activity of nibentan and its analogues

Давыдова, Н. К.; Сизова, О. С.; Vinogradova, S. M.; L'vov, A. I.; Глушков, Р. Г.; Yuzhakov, S. D.; Mashkovskiy, Michail D

doi:10.1016/s0223-5234(00)00116-1

Cited by 7 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of the compounds were found to be more potent than nibentan and possessed a longer duration of action. The antifibrillatory activity of (±)-N-[5-(diethylamino)-1-(4-methoxyphenyl) pentyl]-4-nitrobenzamide hydrochloride was comparable to that of nibentan but exceeded the potency of D-satalol and sematilide [34,35].…”

Section: Miscellaneousmentioning

confidence: 93%

Pharmacological Potential of Benzamide Analogues and their Uses in Medicinal Chemistry

Asif¹

2016

Mod Chem Appl

View full text Add to dashboard Cite

Benzamide derivatives possess different kinds of pharmacological activities like antimicrobial, analgesic, antiinflammatory, anticancer, cardiovascular, and other biological activities. Due to these biologically significances, scientists have interesting to develop various new benzamide derivatives. There is still need to improve the already used benzamide derivatives and search for the new and more effective benzamide derivatives. This review exhibited various pharmacophoric activities of benzamides analogues which are biologically importance.

show abstract

Section: Miscellaneousmentioning

confidence: 93%

Pharmacological Potential of Benzamide Analogues and their Uses in Medicinal Chemistry

Asif¹

2016

Mod Chem Appl

View full text Add to dashboard Cite

show abstract

“…The similarity of compound 1b with BRL‐32872 suggests its mixed mechanism of action as a Class III and IV antiarrhythmic. [ 297 ]…”

Section: Combined Classesmentioning

confidence: 99%

Linked biaromatic compounds as cardioprotective agents

Mokrov

2021

Archiv der Pharmazie

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are widespread in the modern world, and their number is constantly growing. For a long time, CVDs have been the leading cause of morbidity and mortality worldwide. Drugs for the treatment of CVD have been developed almost since the beginning of the 20th century, and a large number of effective cardioprotective agents of various classes have been created. Nevertheless, the need for the design and development of new safe drugs for the treatment of CVD remains. Literature data indicate that a huge number of cardioprotective agents of various generations and mechanisms correspond to a single generalized pharmacophore model containing two aromatic nuclei linked by a linear linker. In this regard, we put forward a concept for the design of a new generation of cardioprotective agents with a multitarget mechanism of action within the indicated pharmacophore model. This review is devoted to a generalization of the currently known compounds with cardioprotective properties and corresponding to the pharmacophore model of biaromatic compounds linked by a linear linker. Particular attention is paid to the history of the creation of these drugs, approaches to their design, and analysis of the structure-action relationship within each class.

show abstract

“…The inhibitory activity of these drugs on B-Raf kinase [11,12] revealed that the substituted benzene sulphonamido group is important for inhibitory activity. On the other hand the molecular entities possessing Heterocyclic/ non heterocyclic and substituted/unsubstituted benzamides have been well investigated to possess antimicrobial [13][14][15][16][17][18][19][20], analgesic, anti-inflammatory [21,22], anticonvulsant [23][24][25][26][27][28], anticancer [29][30][31][32][33], and other biological activities [34][35][36][37][38][39][40][41] and imidazopyridazines being structural analogues of purines were also reported to be promising scaffolds exhibiting a wide range of biological activities [42][43][44][45][46]. In view of these reports, our interest moved to develop new benzamido substituted scaffolds which are isosteric analogs of sulphonamido substituted marketed drugs as possible B-Raf Kinase inhibitors and are expected to acquire different selectivities and novelties.…”

Section: Introductionmentioning

confidence: 99%